Solutions / Strategy and Consulting
Competitive IntelligenceClinical insights for your pharmaceutical competitive intelligence
Map the competitive landscape, positioning, and intensity across disease areas, drug candidates, and sponsor peers, built on a source-traceable, daily-refreshed view of 740,000+ clinical trials.
- 740,000+ trials
- Refreshed daily
- Source-traceable
- Deep China coverage
Answer the pharma competitive intelligence questions that shape your strategy
TrialForge turns global trial data into a working competitive picture, enriched with modern labeling and ontology mapping, so you're confident you're capturing everything, regardless of what investigators typed.
Landscape a disease area
See every active and historical trial, sponsor, and asset in a therapeutic area, with drug modalities, biomarkers tested, and rare disease flags layered on top.
Assess competitive intensity
Quantify how crowded an indication, mechanism, or modality is, see where sponsors are converging, and find the white space that is still open.
Profile sponsor peers
Build a live picture of a competitor's pipeline and trial activity across regions, and understand how their strategy is shifting over time.
Go beyond the registry
Enrich the public record with unified disease names, therapeutic area groupings, modality mapping, decoded drug names, and rare disease context that registries do not surface on their own.
An example landscape, ready in minutes
ALS pipeline landscape
212drug trials
ALS drug trials started 2019 to 2025, still led by small molecules, with antisense RNA therapies the clear number two.
- 1Massachusetts General Hospital10 trials
- 2Sumitomo Pharma7 trials
- 3Amylyx Pharmaceuticals5 trials
- 4Biogen5 trials
- 5Beijing Tiantan Hospital5 trials
ALS Drug Trials by Modality
Started 2019 to 2025, count
| Modality | Trials |
|---|